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Abstract: 
Cytochrome P450 (CYP P450) enzymes are a superfamily of mono-oxygenases that are found in all kingdoms of life. The CYP 
P450 enzymes constitute a large superfamily of haem-thiolate proteins involved in the metabolism of a wide variety of both 
exogenous and endogenous compounds. The CYP activities have been shown to be involved in numerous interactions especially 
between drugs and herbal constituents. The majority of serious cases of drug interactions are as a result of the interference of the 
metabolic clearance of one drug by yet another co-administered drug, food or natural product. Gaining mechanistic knowledge 
towards such interactions has been accepted as an approach to avoid adverse reactions. The inductions and inhibition of CYP 
enzymes by natural products in the presence of a prescribed drug has led to adverse effects. Herbal medicines such as St. John’s 
wort (Hypericum perforatum), garlic (Allium sativa), piperine (from Piper sp.), ginseng (Ginseng sp.), gingko (Gingko biloba), 
soya beans (Glycine max), alfalfa (Medicago sativa) and grape fruit juice show clinical interactions when co-administered with 
medicines. This review documents the involvement of CYP enzymes in the metabolism of known available drugs and herbal 
products. We also document the interactions between herbal constituents & CYP enzymes showing potential drug-herb 
interactions. Data on CYP450 enzymes in activation (i.e. induction or inhibition) with natural constituents is also reviewed. 
Keywords:  Cytochrome P450; CYP; Herb-drug interactions; inhibition; induction; natural products; natural ingredients; 
phytomolecules 
 
Background: 
The name Cytochrome P450 derives from the fact that these 
proteins have a haem group, and an unusual absorption 
spectrum range. The reason for cytochrome P450 to absorb in 
this range is due to the unusual ligand haem iron.  Four 
ligands are provided by nitrogen on the haem ring. The CYP 
enzymes are a superfamily of haem containing enzymes. In 
humans, CYP enzymes are important in the production of 
compounds such as cholesterol, corticosteroids and fatty 
acids. The most important feature of the CYP enzymes is its 
unique ability to activate molecular oxygen and to 
subsequently insert a single oxygen atom stereo-specifically 
into inert chemical bonds. CYP enzymes catalyses the 
insertion of oxygen into activated carbon – hydrogen bonds 
to yield alcohol (e.g. RH + O2 + 2H
+ + 2e
– → ROH + H2O). 
However, they can also carry out plethora of other reactions 
including epoxidation, dealkylation and heteroatom oxidation 
[1]. The majority of serious cases of drug interactions are as a 
result of the interference of the metabolic clearance of one 
drug by yet another co-administered drug, food or natural 
product. Gaining mechanistic knowledge towards such 
interactions has been accepted as an approach, for avoiding 
adverse reactions. The CYP P450 enzymes, which interact 
with a plethora of drugs available in the market, have been 
associated with a majority of the metabolism-related drug- 
drug interactions known to date [2, 3].
  It is not surprising that 
much of the CYP in human is found in the liver, the main 
organ for drug and toxin removal. However, a significant 
amount is also found in the small intestine. There are over a 
thousand different types of CYP known till date. 
Nevertheless, the number of CYP types in human is relatively 
less.  
 
The P450 proteins are categorized into families and 
subfamilies using sequence similarity.  Sequences that are 
greater than 40% identity are considered within a family. 
Sequences that are greater than 55% identity are considered 
within a super-family. Humans have 57 CYP genes and more 
than 59 pseudo-genes divided among 18 families of CYP 
P450 genes and 43 subfamilies. The summary of the genes 
and proteins encoded is given in Table 1 (supplementary 
material). Several of them have been identified as particularly 
important in oxidative metabolism. They are CYP3A4 (by far 
the most important), CYP2D6,  CYP2C9,  and CYP2C19. 
Other notable CYPs are CYP2E1, CYP2A6 and CYP1A2. Bioinformation by Biomedical Informatics Publishing Group                                     open access 
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Enzyme induction occurs for CYP with appropriate 
substrates. The activity of CYP oxidases do vary across 
population due to polymorphism. Such differences in activity 
have clinical consequences, especially when multiple drugs 
are co-administered.  
 
Biological description of cytochrome P450 
The CYP enzymes involved in drug metabolism in humans 
are expressed predominantly in the liver. However, it is also 
present in large and small intestines, lungs and brain. They 
are insoluble proteins bound to the endoplasmic reticulum, 
with complex mechanistic and structural features. However, 
the first crystal structures of mammalian CYP enzymes have 
recently been determined, namely CYP2C5, CYP2B4, 
CYP2C9 and CYP3A4
 [4, 5]
 and thus, much progress can be 
expected in this area in near future. It is believed that 15-20 
different CYP enzyme isoforms contribute to drug 
metabolism in the human liver. However, the CYP enzymes 
1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 are considered most 
important among them [1, 2, 6]. These have different yet 
complementary substrate specificities with ability to 
metabolize a vast array of xenobiotics. CYP3A4 acts on most 
lipophilic substrates and is known to metabolize >50% of the 
drugs in the liver [7], whilst CYP2D6 exhibits a preference 
for positively charged molecules, usually with a basic 
nitrogen. CYP2C9 metabolizes weakly anionic molecules, 
CYP1A2 uses poly-aromatic hydrocarbons and CYP2E1 uses 
small and soluble organics. Therefore, the CYP system can 
metabolize almost any organic xenobiotic [7, 8]. Most drugs 
are cleared by CYP proteins.  Drugs can increase or decrease 
the activity of one or more CYP enzymes, which alters the 
rate at which the drug is degraded and cleared from the body.  
This can work both ways. When a drug increases the activity 
of a CYP protein, CYP can render the drug ineffective, 
because it is cleared too quickly from the body.   
Alternatively, when a drug inhibits a CYP protein, CYP may 
not prevent the drug from accumulating to toxic levels, even 
to the extent of causing an overdose. CYP1, CYP2, CYP3 
and CYP4 are the most important for drug biotransformation 
among CYP proteins and CYP3A4 is the most prevalent CYP 
in the body and is known metabolise several drugs [9, 10, 
11]. 
 
Metabolism based interactions 
The most common form of drug interactions entail a foreign 
chemical acting either as an inhibitor or an inducer of the 
CYP enzyme isoform responsible for metabolizing an 
administered medicinal drug, subsequently leading to an 
unusually slow or fast clearance of the drug. More rarely, 
enzyme stimulation can occur where direct addition of one 
compound enhances the rate of reaction for substrate [3]. 
Inhibition of drug metabolism will result in an elevation of its 
concentration in tissues. This leads to various adverse 
reactions, particularly for drugs with a low therapeutic index. 
Constant research in this field has been successfully kept 
updated by developing web based databases for reported and 
likely drug candidate interactions. The induction of a CYP 
enzyme isoform responsible for the metabolism of a drug can 
reduce its expected therapeutic capacity due to depletion of 
its plasma concentration. A higher dose of the parent drug is 
therefore required for effective therapy, with further dosage 
tailoring as and when the inducer effects are withdrawn. This 
is true in many instances. It should be note that CYP enzyme 
induction rarely leads to toxicity, except in cases where the 
metabolite is particularly harmful. For example, CYP1A1 
and 1A2 have been implicated in increased carcinogenic 
activation of chemicals. Thus they are considered as a 
potential risk factor in certain cancers and hence drugs that 
induce these reactions are preferentially avoided by the 
pharmaceutical industry [10, 12]. Several popular herbs have 
been reported to participate in interactions with medicinal 
drugs leading to clinically relevant drug adversities. A few 
examples that involve CYP enzymes and are highlighted in 
this review along with predicted as well as experimental 
interactions are summarized in Table 2 (supplementary 
material). A few examples of herbal constituents and drugs 
that interact with human CYP enzymes are highlighted in 
Table 3 (see supplementary material). 
 
Hypeforin from St. John’s Wort herb (Hypericum 
perforatum) 
A popular herb largely used in the treatment of depression is 
St. John's Wort (SJW). It has been implicated with a number 
of clinically significant interactions with medicinal drugs, 
one of the more potentially fatal being with cyclosporine.   
Cyclosporine is an immunosuppressant with a narrow 
therapeutic index administered to transplant patients. In 
reported cases, consumption of various levels of SJW (from 
300 mg/day for 4 weeks to 2 or 3 × 300 mg/day for 6 
months) lead to a decrease in cyclosporine levels below the 
desirable effective therapeutic range of 200-350 μg/L causing 
cellular rejection of the tissue [13]. The induction of 
CYP3A4 through the activation of pregnane X-receptor by 
both the crude extract and hyperforin (one of the active 
ingredients) has been demonstrated in primary human 
hepatocyte cultures. In addition, the induction of intestinal 
multidrug resistant transporter protein MDR1/P-glycoprotein 
has been demonstrated in clinical and preclinical (rat in vivo) 
investigations [14, 15]. Results of these studies explain the 
combined increase in absorption and metabolism of drugs 
such as cyclosporine in the presence of SJW, thus resulting in 
a severe decrease in the serum availability of the drug leading 
to declined therapy. They also provide a mechanism-based 
explanation for other SJW-mediated adversities in the 
presence of prescription medicines whose metabolism is 
catalyzed by CYP3A4. Such instances include the loss of 
anticoagulant activity of warfarin and the intermenstrual 
bleeding in several females on the contraceptive, 
ethinylestradiol [16, 17]. A recent clinical study examining 
the metabolism of omeprazole has established that in addition 
to the induction of CYP3A4, SJW enormously decreases the 
plasma concentration of the drug through the induction of 
CYP2C19, which is responsible for the hydroxylation of the 
drug [18].        
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Allicin from Garlic (Allium sativum) 
Garlic is used for the reduction of hypertension and 
hyperlipidaemia. It has been implicated in the decrease of the 
plasma concentration of protease inhibitor saquinavir [19, 
20]. The induction of gut CYP3A4 by garlic was thought to 
be a plausible explanation for the reduction in bioavailability 
of the drug known to be primarily metabolized by CYP3A4 
[21]. The active ingredient allicin has also shown potent 
inhibitory activity on CYP2C9 and 2C19. The potential drug 
adversities predicted for each of these active ingredients as a 
result of their interactions with CYP enzymes has to be 
examined in a clinical setting to know the extent to which 
garlic can interact with co-medications [20, 22]. 
 
Piperine from Piper (Piper nigrum) 
In clinical trials, piperine has shown to increase the 
bioavailability of phenytoin, propranolol and theophylline 
[23]. Although in vivo study on rat has demonstrated that 
piperine treatment suppressed CYP2E1 expression and 
enhanced 2B and 1A expression [12, 24]. It should be noted 
that the clinical observations are due for CYP isoforms for 
further research. 
 
Ginsenoside from Ginseng (Panax ginseng) 
Ginseng (Panax ginseng) has been shown to induce mania 
when used concomitantly with phenelzine [25]. Bipolar 
disorder (mania) also known as manic depression (or bipolar 
depression) and is a common mood disorder that affects 
about 5.7 million Americans 
(www.medicinenet.com/bipolar_disorder/article.htm).  In 
vitro studies using both crude ginseng extract and total 
saponins at high concentrations (>2000 μg/mL) showed the 
inhibition of CYP2E1 activity in mouse and human 
microsomes  [26]. Ginsenoside caused weak inhibitory 
activity against CYP3A4, CYP2D6, CYP2C19 and CYP2C9 
while ginsenoide increased the activity of CYP2C9 and 
CYP3A4 [26, 27]. The effect of this herb and its ingredients 
on CYP enzymes is yet to be substantiated in an in vivo 
context.             
 
Ginkgolic acid from Gingko (Gingko biloba) 
In vitro and in vivo analysis carried out on hepatic and 
intestinal CYP enzymes of rat, have demonstrated that the 
leaf extract inhibits the metabolism of diltiazem, which is a 
typical substrate for CYP3A [28] and also induces CYP2B 
enzymes [29]. In addition, ginkgolic acids were shown to be 
potent inhibitors of CYP1A2, CYP2C9 and CYP2C19 under 
CYP enzymes case study [30]. Although flavanol aglycones 
showed significant inhibitory activity against CYP1A2, 2C9 
and 3A, recent findings showed that the most abundant 
components of gingko preparations in clinical use (terpene 
trilactones and flavanol glycosides) do not significantly 
inhibit major CYP enzymes in microsomes of human’s liver 
[16, 22, 29]. The variations of constituents of gingko 
(ginkgolides, biobalides, and flavone glycosides) and their 
bioavailabilities could explain the disparity in findings, in 
addition to species variability in drug metabolism. 
 
Pharmacovigilance  
The under-reporting of adverse drug reactions in developing 
countries including India, Sri Lanka and the Philippines [31], 
is possibly the main reason why only 3% of the adverse drug 
reactions reported in the WHO database have been added 
from the developing countries where approximately 80% of 
the world's population lives. In these countries, a strong 
practice of traditional medicine exists and adverse drug 
reactions go unrecognized as part of the healing process. 
There is generally a misconception that natural therapies are 
safe. The reluctance of physicians trained in Western 
medicine to give recognition to these traditional practices 
also leads to a lack of acknowledgement of possible drug-
herb interactions [32]. The world consumption of natural 
products for medicinal purposes is immense. According to 
WHO estimates, 30-50% of total medicinal consumption in 
China can be accounted by herbal preparations, 70% of 
Canadians and >50% of Europeans, North Americans and 
persons living in other industrialized regions have used 
complementary medicine at least once, in addition to the high 
incidence of practice in Africa, Latin America and Asia [8, 
33, 34].  
 
Future prospects: 
The role of metabolism in drug-herb components interactions 
and in turn the role of CYP enzymes in such interactions 
cannot be overstated. Studies that could establish the various 
phenotypes and genotypes of CYP alleles for populations in 
various ethnic groups, the impact of environmental, dietary 
and social habits on CYP activity, the metabolism of natural 
products by CYP enzymes and the impact of these natural 
products on the CYP enzyme activities would allow initial 
predictions. Hence, prevention of likely adverse drug 
reactions involving these crucial enzymes is possible. 
Gaining a mechanism based understanding lies at the root of 
avoiding these enzyme-related drug adversities. Cytochrome 
P450 is an ideal target for these studies. The ability to make 
such predictions would be of enormous benefit to 
pharmacogenomics studies as P450 plays a vital role in the 
metabolism of drugs. The Cytochrome is of special interest in 
pharmacology as it is responsible for the metabolism of many 
pharmacologically active molecules. The use of in silico 
protein–drug interactions studies and computer aided drug 
designing approach and quantum mechanical calculations 
will allowing to know the mechanism of interaction of P450 
with herbal constituents. This in turn will allow theories 
regarding unknown features of human P450 to be tested and 
predictions to be made for the result of an interaction of 
herbal constituents within a given P450. The computational 
approaches could be used to analyze the interactions, 
regarding the processes on such binding which helps to 
predict new conformations of active site. The introduction of 
some of the determined contact residues of the active site into 
the model will allow the orientation of herbal constituents 
and lead molecules. 
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Supplementary material 
 
CYP 
family 
Function Category  CYP 
Isoform 
CYP1  Drug and steroid (especially estrogen) metabolism  3 subfamilies,  
3 genes, 
1 pseudogene 
CYP1A1 
CYP1A2 
CYP1B1  
CYP2  Drug and steroid metabolism  13 subfamilies, 
16 genes, 
16 pseudogenes 
  
  
  
  
  
  
CYP2A6 CYP2A7 CYP2A13 
CYP2B6  
CYP2C8  
CYP2C9 CYP2C18 CYP2C19 
CYP2D6  
CYP2E1  
CYP2F1  
CYP2J2  
CYP2R1  
CYP2S1  
CYP2U1 
CYP2W1 
CYP3  Drug and steroid (including testosterone) metabolism  1 subfamily,  
4 genes,  
2 pseudogenes 
CYP3A4 CYP3A5 CYP3A7 
CYP3A43 
CYP4  Arachidonic acid or fatty acid metabolism  6 subfamilies, 
11 genes,  
10 pseudogenes 
  
  
CYP4A11 CYP4A22 CYP4B1 
 CYP4F2  
CYP4F3  
CYP4F8 CYP4F11 CYP4F12 
CYP4F22 CYP4V2 CYP4X1  
CYP4Z1 
CYP5  Thromboxane A2 synthase  1 subfamily,  
1 gene 
CYP5A1 
CYP7  Bile acid biosynthesis 7-alpha hydroxylase of steroid nucleus  2 subfamilies,  
2 genes 
CYP7A1  
CYP7B1 
CYP8  Varied  2 subfamilies,  
2 genes 
CYP8A1 (prostacyclin synthase), 
CYP8B1 (bile acid biosynthesis) 
CYP11  Steroid biosynthesis  2 subfamilies,  
3 genes 
CYP11A1 CYP11B1 CYP11B2 
CYP17  Steroid biosynthesis, 17-alpha hydroxylase  1 subfamily,  
1 gene 
CYP17A1 
CYP19  Steroid biosynthesis: aromatase synthesizes estrogen  1 subfamily,  
1 gene 
CYP19A1 
CYP20 Unknown  function  1 subfamily,  
1 gene 
CYP20A1 
CYP21  Steroid biosynthesis  2 subfamilies,  
2 genes,  
1 pseudogene 
CYP21A2 
CYP24  Vitamin d degradation  1 subfamily,  
1 gene 
CYP24A1 
CYP26  Retinoic acid hydroxylase  3 Subfamilies,  
3 genes 
CYP26A1 CYP26B1 CYP26C1 Bioinformation by Biomedical Informatics Publishing Group                                     open access 
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CYP27  Varied  3 subfamilies,  
3 genes 
CYP27A1 (bile acid biosynthesis), 
CYP27B1 (vitamin D3 1-alpha 
hydroxylase, activates vitamin D3) 
CYP27C1 (unknown function) 
CYP39  7-alpha hydroxylation of 24-hydroxycholesterol  1 subfamily,  
1 gene 
CYP39A1 
CYP46 Cholesterol  24-hydroxylase  1 subfamily,  
1 gene 
CYP46A1 
CYP51 Cholesterol  biosynthesis  1 subfamily,  
1 gene, 
3 pseudogenes 
CYP51A1 (lanosterol 14-alpha 
demethylase) 
Table 1: Classification of the CYP family on the basis of CYP isoform and function is given. 
 
S. No.  Name of medicinal 
plant 
Herbal component 
and Chemical 
formula 
IUPAC name  PubChem 
CID* 
1. St.John’s  wort 
(Hypericum 
perforatum) 
Hyperforin    
C35H52O4
4-Hydroxy-5-isobutyryl-6-methyl-1,3,7-tris-(3-
methyl-but-2-enyl)-6-(4-methyl-pent-3-enyl)-
bicyclo[3.3.1]non-3-ene-2,9-dione 
5288591 
2. Garlic 
(Allium sativum) 
Allicin 
C6H10OS2
3-prop-2-enylsulfinylsulfanylprop-1-ene 65036 
3. Piperine 
(Piper nigrum) 
Piperine 
C17H19NO3
(2E,4E)-5-(1,3-benzodioxol-5-yl)-1-piperidin-1-
ylpenta-2,4-dien-1-one 
638024 
4. Ginseng 
(Panax ginseng) 
Ginsenoside 
C30H52O2
(3S,5R,8R,9R,10R,14R,17S)-17-(2-hydroxy-6-
methylhept-5-en-2-yl)-4,4,8,10,14-pentamethyl-
2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-
cyclopenta[a]phenanthren-3-ol 
3086007 
5. Gingko 
(Ginkgo biloba) 
Ginkgolic acid 
C22H34O3
2-hydroxy-6-[(Z)-pentadec-8-enyl]benzoic acid  5281858 
Table 2: Medicinal plants with their herbal components, IUPAC name, Chemical structure and PubChem CID number. (Note: * 
= PubChem compound identity descriptor number (http://pubchem.ncbi.nlm.nih.gov/)). 
 
 S. No.  Medicinal 
plant 
Herbal 
constituent 
and  
chemical 
formula 
Drug Experimental 
model 
CYP 
enzyme 
involved 
(isoform) 
Symptom of 
interaction 
Mechanism 
1. St.  John’s 
wort 
(Hypericum 
perforatum) 
Hyperforin 
C35H52O4
 
Ciclosporin Human 
hepatocytes 
 
CYP3A4, 
2E1, 2C19 
Reduction in 
serum 
Induction of p-
glycoprotein 
2. St.  John’s 
wort 
(Hypericum 
perforatum) 
Hyperforin 
C35H52O4
 
Warfarn Human  clinical 
trail 
CYP3A4 Loss  of 
anticoagulant 
activity 
Inhibition of 
CYP activity 
3. St.  John’s 
wort 
(Hypericum 
perforatum) 
Hyperforin 
C35H52O4
 
Omeprazole Human  clinical 
trail 
CYP2C19 Decreases  Plasma 
concentration 
Induction of 
CYP2C19 , 
3A4 
4. Garlic   
(Allium 
sativum) 
Allicin 
C6H10OS2
Sequinavir Human  clinical 
trail 
CYP3A4 Reduction  of 
hypertension 
Inhibition of 
CYP2C9, 
2C19, 3A4 
5. Garlic   
(Allium 
sativum) 
Allicin 
C6H10OS2
Sequinavir Human  clinical 
trail 
CYP2C9, 
2C19 
Reduction of 
hypertension and 
hyperlipidameia 
Inhibition of 
CYP2C9, 
2C19 
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6. 
 
 
Black 
Pepper 
(Piper 
nigrum) 
Piperine 
C17H19NO3
Antimicrobial  In vivo studies in 
rat 
CYP2E1 suppressed 
CYP2E1 
expression 
Induce activity 
of 
CYP 1A , 2B 
7. Ginseng   
(Panax 
ginseng) 
Ginsenoside  
C42H72O14 , 
Ginsenoide 
Phenelzine  In vitro studies in 
mouse and human 
microsomes 
 
CYP2E1 
Induce CYP3A4, 
2D6, 2C19 , 2C9 
activity 
Inhibition of 
CYP2E1 
activity 
 
8. 
Gingko  
(Gingko 
biloba) 
Ginkgolic 
acid 
C22H34O3
Diltiazem  In vitro and in 
vivo analysis on 
rat hepatic and 
intestinal CYP 
enzymes 
CYP3A, 
2B 
Inhibit 
metabolism of  
Diltiazem (drug) 
Induces 
CYP2B and 
inhibit 
CYP1A2, C9 
2C19 
Table 3: Assessment of herbal components on drug interactions and effects on CYP activities 
 